FDA OKs Breckenridge's ANDA for rizatriptan benzoate

01/2/2013 | Pharmaceutical Business Review Online

Breckenridge Pharmaceutical's abbreviated new-drug application for rizatriptan benzoate tablets received FDA approval. The tablet, manufactured by Natco Pharma, is the bioequivalent of Merck & Co.'s prescription migraine drug Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ